During the last 20 years, pharmaceutical industry and academic eforts have led to several structurally unrelated classes of non peptide cholecystokinin-1 receptor antagonista. Due to the lack of high resolution structure of CCK1-R and its peptide ligand, different strategies to design antagonists have been adopted.
